TRADES
Latest Trades
90
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 25 Feb 2022 Buy FATE FATE THERAPEUTICS INC 23,351 0.0216
ARKG 24 Feb 2022 Buy FATE FATE THERAPEUTICS INC 6,353 0.0061
ARKG 23 Feb 2022 Buy FATE FATE THERAPEUTICS INC 103,763 0.0957
ARKG 22 Feb 2022 Buy FATE FATE THERAPEUTICS INC 86,612 0.0795
ARKK 27 Dec 2021 Sell FATE FATE THERAPEUTICS INC 13,150 0.0048
ARKG 15 Dec 2021 Buy FATE FATE THERAPEUTICS INC 71,797 0.0678
ARKG 14 Dec 2021 Buy FATE FATE THERAPEUTICS INC 196,581 0.1821
ARKG 8 Sep 2021 Buy FATE FATE THERAPEUTICS INC 55,010 0.0500
ARKK 8 Sep 2021 Buy FATE FATE THERAPEUTICS INC 74,729 0.0200
ARKK 7 Sep 2021 Buy FATE FATE THERAPEUTICS INC 48,314 0.0200
ARKG 3 Sep 2021 Buy FATE FATE THERAPEUTICS INC 74,850 0.0600
ARKK 3 Sep 2021 Buy FATE FATE THERAPEUTICS INC 162,959 0.0500
ARKK 2 Sep 2021 Buy FATE FATE THERAPEUTICS INC 148,263 0.0500
ARKK 1 Sep 2021 Buy FATE FATE THERAPEUTICS INC 1,075 0.0004
ARKG 31 Aug 2021 Buy FATE FATE THERAPEUTICS INC 62,266 0.0534
ARKK 30 Aug 2021 Buy FATE FATE THERAPEUTICS INC 89,825 0.0294
ARKG 27 Aug 2021 Buy FATE FATE THERAPEUTICS INC 57,841 0.0509
ARKK 27 Aug 2021 Buy FATE FATE THERAPEUTICS INC 114,617 0.0378
ARKK 26 Aug 2021 Buy FATE FATE THERAPEUTICS INC 60,075 0.0193
ARKK 25 Aug 2021 Buy FATE FATE THERAPEUTICS INC 1,000 0.0003
ARKG 24 Aug 2021 Buy FATE FATE THERAPEUTICS INC 171,840 0.1497
ARKK 24 Aug 2021 Buy FATE FATE THERAPEUTICS INC 357,508 0.1171
ARKG 23 Aug 2021 Buy FATE FATE THERAPEUTICS INC 55,219 0.0489
ARKK 23 Aug 2021 Buy FATE FATE THERAPEUTICS INC 151,829 0.0502
ARKG 20 Aug 2021 Buy FATE FATE THERAPEUTICS INC 105,042 0.0949
ARKK 20 Aug 2021 Buy FATE FATE THERAPEUTICS INC 292,854 0.0982
ARKK 18 Aug 2021 Buy FATE FATE THERAPEUTICS INC 102 0.0000
ARKK 17 Aug 2021 Buy FATE FATE THERAPEUTICS INC 32,533 0.0125
ARKK 16 Aug 2021 Buy FATE FATE THERAPEUTICS INC 65,163 0.0244
ARKK 11 Aug 2021 Buy FATE FATE THERAPEUTICS INC 159,503 0.0630
ARKK 10 Aug 2021 Buy FATE FATE THERAPEUTICS INC 21,200 0.0082
ARKG 4 Aug 2021 Buy FATE FATE THERAPEUTICS INC 82,289 0.0798
ARKK 4 Aug 2021 Buy FATE FATE THERAPEUTICS INC 30,751 0.0114
ARKG 3 Aug 2021 Buy FATE FATE THERAPEUTICS INC 55,163 0.0548
ARKK 3 Aug 2021 Buy FATE FATE THERAPEUTICS INC 186,114 0.0678
ARKG 2 Aug 2021 Buy FATE FATE THERAPEUTICS INC 27,556 0.0273
ARKG 30 Jul 2021 Buy FATE FATE THERAPEUTICS INC 77,889 0.0754
ARKG 29 Jul 2021 Buy FATE FATE THERAPEUTICS INC 69,851 0.0689
ARKG 28 Jul 2021 Buy FATE FATE THERAPEUTICS INC 8,774 0.0084
ARKG 27 Jul 2021 Buy FATE FATE THERAPEUTICS INC 45,936 0.0416
ARKK 27 Jul 2021 Buy FATE FATE THERAPEUTICS INC 96,037 0.0337
ARKK 26 Jul 2021 Buy FATE FATE THERAPEUTICS INC 85,505 0.0308
ARKK 23 Jul 2021 Buy FATE FATE THERAPEUTICS INC 74,121 0.0270
ARKK 22 Jul 2021 Buy FATE FATE THERAPEUTICS INC 82,301 0.0304
ARKK 21 Jul 2021 Buy FATE FATE THERAPEUTICS INC 38,816 0.0142
ARKK 20 Jul 2021 Buy FATE FATE THERAPEUTICS INC 36,661 0.0137
ARKK 19 Jul 2021 Buy FATE FATE THERAPEUTICS INC 92,286 0.0336
ARKK 16 Jul 2021 Buy FATE FATE THERAPEUTICS INC 57,875 0.0206
ARKG 15 Jul 2021 Buy FATE FATE THERAPEUTICS INC 152,712 0.1345
ARKG 14 Jul 2021 Buy FATE FATE THERAPEUTICS INC 70,126 0.0602
ARKK 8 Jul 2021 Buy FATE FATE THERAPEUTICS INC 32,305 0.0115
ARKK 7 Jul 2021 Buy FATE FATE THERAPEUTICS INC 535,305 0.1894
ARKK 11 May 2021 Buy FATE FATE THERAPEUTICS INC 64,210 0.0241
ARKG 10 May 2021 Buy FATE FATE THERAPEUTICS INC 52,093 0.0483
ARKK 10 May 2021 Buy FATE FATE THERAPEUTICS INC 204,170 0.0775
ARKG 7 May 2021 Buy FATE FATE THERAPEUTICS INC 47,898 0.0432
ARKG 6 May 2021 Buy FATE FATE THERAPEUTICS INC 224,009 0.1973
ARKK 12 Apr 2021 Buy FATE FATE THERAPEUTICS INC 139,699 0.0436
ARKK 6 Apr 2021 Buy FATE FATE THERAPEUTICS INC 102,269 0.0342
ARKK 5 Apr 2021 Buy FATE FATE THERAPEUTICS INC 31,423 0.0109
ARKK 31 Mar 2021 Buy FATE FATE THERAPEUTICS INC 2,660 0.0009
ARKK 30 Mar 2021 Buy FATE FATE THERAPEUTICS INC 35,468 0.0123
ARKK 29 Mar 2021 Buy FATE FATE THERAPEUTICS INC 129,997 0.0444
ARKK 25 Mar 2021 Buy FATE FATE THERAPEUTICS INC 306,976 0.1075
ARKK 24 Mar 2021 Buy FATE FATE THERAPEUTICS INC 136,815 0.0521
ARKK 23 Mar 2021 Buy FATE FATE THERAPEUTICS INC 31,614 0.0117
ARKK 19 Mar 2021 Buy FATE FATE THERAPEUTICS INC 13,068 0.0049
ARKK 18 Mar 2021 Buy FATE FATE THERAPEUTICS INC 84,421 0.0314
ARKK 17 Mar 2021 Buy FATE FATE THERAPEUTICS INC 18,860 0.0066
ARKK 8 Mar 2021 Buy FATE FATE THERAPEUTICS INC 93,230 0.0368
ARKK 5 Mar 2021 Buy FATE FATE THERAPEUTICS INC 163,146 0.0617
ARKK 4 Mar 2021 Buy FATE FATE THERAPEUTICS INC 229,307 0.0894
ARKK 3 Mar 2021 Buy FATE FATE THERAPEUTICS INC 148,508 0.0577
ARKK 23 Feb 2021 Buy FATE FATE THERAPEUTICS INC 154,781 0.0556
ARKK 22 Feb 2021 Buy FATE FATE THERAPEUTICS INC 34,505 0.0132
ARKK 18 Feb 2021 Buy FATE FATE THERAPEUTICS INC 34,007 0.0127
ARKK 17 Feb 2021 Buy FATE FATE THERAPEUTICS INC 79,517 0.0287
ARKK 16 Feb 2021 Buy FATE FATE THERAPEUTICS INC 26,283 0.0096
ARKK 12 Feb 2021 Buy FATE FATE THERAPEUTICS INC 34,300 0.0125
ARKK 11 Feb 2021 Buy FATE FATE THERAPEUTICS INC 35,519 0.0133
ARKK 10 Feb 2021 Buy FATE FATE THERAPEUTICS INC 11,980 0.0046
ARKK 4 Feb 2021 Buy FATE FATE THERAPEUTICS INC 56,095 0.0227
ARKK 3 Feb 2021 Buy FATE FATE THERAPEUTICS INC 98,059 0.0394
ARKK 2 Feb 2021 Buy FATE FATE THERAPEUTICS INC 5,878 0.0023
ARKK 1 Feb 2021 Buy FATE FATE THERAPEUTICS INC 154,509 0.0608
ARKK 29 Jan 2021 Buy FATE FATE THERAPEUTICS INC 95,867 0.0400
ARKK 28 Jan 2021 Buy FATE FATE THERAPEUTICS INC 1,515 0.0000
ARKK 27 Jan 2021 Buy FATE FATE THERAPEUTICS INC 160,000 0.0611
ARKG 17 Dec 2020 Sell FATE FATE THERAPEUTICS INC 128,652 0.1934
ARKG 7 Dec 2020 Sell FATE FATE THERAPEUTICS INC 174,345 0.2889
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.